Xenon Pharmaceuticals Company Profile (NASDAQ:XENE)

About Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals logoXenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XENE
  • CUSIP: N/A
  • Web: www.xenon-pharma.com
Capitalization:
  • Market Cap: $71.08 million
  • Outstanding Shares: 17,996,000
Average Prices:
  • 50 Day Moving Avg: $3.99
  • 200 Day Moving Avg: $6.82
  • 52 Week Range: $3.65 - $9.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.80
  • P/E Growth: -0.10
Sales & Book Value:
  • Annual Revenue: $1.22 million
  • Price / Sales: 58.27
  • Book Value: $3.18 per share
  • Price / Book: 1.24
Profitability:
  • EBIDTA: ($26,400,000.00)
  • Net Margins: -449.72%
  • Return on Equity: -34.72%
  • Return on Assets: -32.94%
Debt:
  • Current Ratio: 17.97%
  • Quick Ratio: 17.97%
Misc:
  • Average Volume: 160,790 shs.
  • Beta: 1.44
  • Short Ratio: 1.75
 

Frequently Asked Questions for Xenon Pharmaceuticals (NASDAQ:XENE)

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.10. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.40 million. Xenon Pharmaceuticals had a negative net margin of 449.72% and a negative return on equity of 34.72%. View Xenon Pharmaceuticals' Earnings History.

Where is Xenon Pharmaceuticals' stock going? Where will Xenon Pharmaceuticals' stock price be in 2017?

5 analysts have issued 12-month price objectives for Xenon Pharmaceuticals' stock. Their predictions range from $13.00 to $20.00. On average, they expect Xenon Pharmaceuticals' share price to reach $16.30 in the next year. View Analyst Ratings for Xenon Pharmaceuticals.

What are analysts saying about Xenon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xenon Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. " (5/16/2017)
  • 2. Jefferies Group LLC analysts commented, "Several key ph.II readouts, XEN801 in acne (March) and TV-45070 in post-herpetic neuralgia (PHN) (mid-year), should provide sig. NT stock catalysts. Based on our analyses, our view is their acne and pain programs collectively could generate $1.5B cumulative future royalties/milestones if successful, and a valuation we believe overly discounts the promise of their pipeline and platform, we view reward/risk favorably. Assuming at Buy with $13 PT." (3/13/2017)

Who are some of Xenon Pharmaceuticals' key competitors?

Who owns Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (4.04%), Tekla Capital Management LLC (1.95%), Endurant Capital Management LP (1.90%), Sphera Funds Management LTD. (1.83%), Point72 Asset Management L.P. (1.73%) and Sabby Management LLC (1.65%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Ian Mortimer and Y Paul Goldberg. View Institutional Ownership Trends for Xenon Pharmaceuticals.

Who sold Xenon Pharmaceuticals stock? Who is selling Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC and Perceptive Advisors LLC. View Insider Buying and Selling for Xenon Pharmaceuticals.

Who bought Xenon Pharmaceuticals stock? Who is buying Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Endurant Capital Management LP, Sabby Management LLC, Renaissance Technologies LLC, K2 Principal Fund L.P. and KCG Holdings Inc.. View Insider Buying and Selling for Xenon Pharmaceuticals.

How do I buy Xenon Pharmaceuticals stock?

Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Xenon Pharmaceuticals stock cost?

One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $3.95.

Analyst Ratings

Consensus Ratings for Xenon Pharmaceuticals (NASDAQ:XENE) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.30 (312.66% upside)

Analysts' Ratings History for Xenon Pharmaceuticals (NASDAQ:XENE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/13/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$13.00MediumView Rating Details
3/11/2017Canaccord GenuitySet Price TargetBuy$16.00MediumView Rating Details
12/22/2016Bloom BurtonInitiated CoverageBuy$14.50N/AView Rating Details
10/21/2016Stifel NicolausInitiated CoverageBuy$18.00N/AView Rating Details
9/26/2016GuggenheimInitiated CoverageBuy -> Buy$20.00N/AView Rating Details
9/24/2015SEB Equity ResearchReiterated RatingPositiveN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)
Earnings by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Earnings History by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/201712/31/2016($0.42)($0.32)$0.40 million$0.38 millionViewListenView Earnings Details
11/3/2016Q316($0.43)($0.51)$0.40 million$0.41 millionViewListenView Earnings Details
8/3/2016Q216($0.48)($0.42)$0.50 million$0.41 millionViewN/AView Earnings Details
5/10/2016Q116($0.21)($0.23)$3.30 million$0.60 millionViewListenView Earnings Details
3/8/2016Q415($0.16)($0.27)$4.90 million$3.23 millionViewListenView Earnings Details
11/10/2015Q315($0.02)($0.27)$4.65 million$4.29 millionViewListenView Earnings Details
8/10/2015Q215($0.16)($0.07)$4.90 million$4.05 millionViewListenView Earnings Details
5/12/2015Q115$0.14($0.30)$4.65 million$4.00 millionViewListenView Earnings Details
3/12/2015Q4($0.09)$1.57$5.10 million$4.43 millionViewListenView Earnings Details
12/15/2014$0.41$1.69$5.00 million$13.19 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)
2017 EPS Consensus Estimate: ($0.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.37)($0.37)($0.37)
Q4 20171$0.25$0.25$0.25
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xenon Pharmaceuticals (NASDAQ:XENE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Xenon Pharmaceuticals (NASDAQ:XENE)
Insider Ownership Percentage: 11.10%
Institutional Ownership Percentage: 55.34%
Insider Trades by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Insider Trades by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Frank A HollerDirectorSell30,000$7.85$235,500.00View SEC Filing  
8/19/2016Frank A HollerDirectorSell11,938$7.65$91,325.70View SEC Filing  
8/18/2016Frank A HollerDirectorSell18,062$7.93$143,231.66View SEC Filing  
6/24/2016Ian MortimerCFOBuy5,300$6.22$32,966.00View SEC Filing  
9/24/2015Y. Paul GoldbergVPSell22,149$8.88$196,683.12View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Xenon Pharmaceuticals (NASDAQ:XENE)
Latest Headlines for Xenon Pharmaceuticals (NASDAQ:XENE)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Expect Xenon Pharmaceuticals Inc (XENE) Will Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - May 26 at 10:11 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 7:50 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:58 PM
americanbankingnews.com logoAnalysts Set Expectations for Xenon Pharmaceuticals Inc's FY2017 Earnings (XENE)
www.americanbankingnews.com - May 12 at 11:44 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - May 11 at 4:46 PM
americanbankingnews.com logoJefferies Group Analysts Cut Earnings Estimates for Xenon Pharmaceuticals Inc (XENE)
www.americanbankingnews.com - May 11 at 3:40 PM
finance.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 3:19 PM
finance.yahoo.com logoInvestor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 8:14 PM
finance.yahoo.com logoXenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 8:14 PM
marketbeat.com logoXenon Pharmaceuticals reports 1Q loss
marketbeat.com - May 9 at 7:04 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:20 AM
americanbankingnews.com logo Analysts Expect Xenon Pharmaceuticals Inc (XENE) Will Announce Quarterly Sales of $450,000.00
www.americanbankingnews.com - May 4 at 12:02 PM
americanbankingnews.com logoXenon Pharmaceuticals (XENE) Earns Daily News Impact Rating of 0.14
www.americanbankingnews.com - May 4 at 8:24 AM
finance.yahoo.com logoNuventra founder inks deal for new venture that could be worth as much as $49 million
finance.yahoo.com - April 29 at 2:42 AM
finance.yahoo.com logoXenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 29 at 2:42 AM
americanbankingnews.com logoXenon Pharmaceuticals (XENE) Earning Somewhat Critical Press Coverage, Report Shows
www.americanbankingnews.com - April 28 at 8:32 AM
finance.yahoo.com logoXenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
finance.yahoo.com - April 26 at 8:10 AM
feeds.benzinga.com logoXenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
feeds.benzinga.com - April 26 at 7:01 AM
americanbankingnews.com logoXenon Pharmaceuticals (XENE) Receiving Positive News Coverage, Report Finds
www.americanbankingnews.com - April 25 at 3:14 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 24 at 9:43 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Short Interest Update
www.americanbankingnews.com - April 22 at 5:17 PM
americanbankingnews.com logoXenon Pharmaceuticals (XENE) Receiving Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - April 21 at 7:50 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Expected to Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - April 11 at 2:12 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 12:38 PM
rttnews.com logoXenon Pharmaceuticals Inc. (XENE) Plunged To A New Low After Study Failed
www.rttnews.com - March 27 at 8:01 PM
streetinsider.com logoXenon Pharmaceuticals (XENE) Says XEN801 Missed Efficacy Endpoints in Phase 2 Trial in Patients with Moderate to Severe Acne
www.streetinsider.com - March 24 at 3:47 PM
rttnews.com logoXenon Pharmaceuticals Inc. (XENE) Has Plunged To A New Low After Study Failed
www.rttnews.com - March 24 at 3:47 PM
finance.yahoo.com logoXenon Pharmaceuticals' acne drug fails mid-stage study
finance.yahoo.com - March 24 at 3:47 PM
finance.yahoo.com logoShares slump after Xenon Pharmaceuticals abandons acne drug
finance.yahoo.com - March 24 at 3:47 PM
investopedia.com logoXenon Pharma Dumps Acne Drug After Study Failure
www.investopedia.com - March 24 at 3:47 PM
investorplace.com logoXenon Pharmaceuticals Inc (XENE) Plunges on Acne Drug Flop
investorplace.com - March 24 at 1:13 PM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 15 at 5:46 AM
us.rd.yahoo.com logoCoverage initiated on Xenon Pharmaceuticals by Jefferies
us.rd.yahoo.com - March 13 at 8:23 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Receives New Coverage from Analysts at Jefferies Group LLC
www.americanbankingnews.com - March 13 at 4:28 PM
us.rd.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 8-Mar-17 9:30pm GMT
us.rd.yahoo.com - March 10 at 6:10 AM
biz.yahoo.com logoQ4 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 9 at 5:49 AM
us.rd.yahoo.com logoXenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update
us.rd.yahoo.com - March 9 at 5:49 AM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - March 9 at 5:49 AM
finance.yahoo.com logoXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2016 Financial Results and Provide Corporate Update
finance.yahoo.com - March 2 at 2:02 AM
finance.yahoo.com logoXenon Pharmaceuticals Outlines Key Milestones for 2017
finance.yahoo.com - February 25 at 4:34 AM
us.rd.yahoo.com logo4:39 am Xenon Pharmaceuticals outlines key milestones for 2017; expects topline data from XEN801 Phase 2 clinical trial for acne
us.rd.yahoo.com - January 9 at 3:23 PM
rttnews.com logoEXAS Abuzz, MACK Makes Deal With Ipsen, XENE Awaits Data
www.rttnews.com - January 9 at 4:50 AM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
biz.yahoo.com - January 4 at 7:51 AM
finance.yahoo.com logoWilbur Ross Sells 2 Holdings, Trims Another
finance.yahoo.com - December 1 at 10:04 PM
finance.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 3-Nov-16 8:30pm GMT
finance.yahoo.com - November 29 at 1:26 PM
finance.yahoo.com logoXENON PHARMACEUTICALS INC. Financials
finance.yahoo.com - November 23 at 8:40 PM
finance.yahoo.com logoXenon Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
finance.yahoo.com - November 8 at 8:29 PM
biz.yahoo.com logoQ3 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - November 3 at 12:49 PM
finance.yahoo.com logoCoverage initiated on Xenon Pharmaceuticals by Guggenheim
finance.yahoo.com - September 26 at 8:08 PM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - September 9 at 7:47 PM

Social

Chart

Xenon Pharmaceuticals (XENE) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff